Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.62 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037442 | 1.00 | DRD2 (0.62) | DRD2DRD3CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3037511 | 0.98 | DRD2 (0.60) | DRD2DRD3CYP2D6SLC6A2SLC6A4 | |
| Bromide SCHEMBL3041691 | 0.98 | DRD2 (0.60) | DRD2DRD3CYP2D6SLC6A2SLC6A4 | |
| Bromide SCHEMBL567330 | 0.98 | DRD2 (0.60) | DRD2DRD3CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3037509 | 0.98 | DRD2 (0.60) | DRD2DRD3CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL11768645 | 0.95 | DRD3 (0.56) | DRD2DRD3CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7405883 | 0.91 | DRD2 (0.55) | DRD2DRD3 | |
| Tert-Butyl Formate SCHEMBL27616090 | 0.84 | DRD2 (0.47) | DRD2DRD3SIGMAR1NFKB1PRCP | |
| Hydrochloric Acid SCHEMBL4619059 | 0.82 | CHRNB2 (0.52) | DRD2DRD3 | |
| SCHEMBL1658753 | 0.81 | HDAC4 (0.56) | DRD2DRD3SIGMAR1NFKB1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-9850206-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2925721-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2176252-B1 | 2, 3-DIHYDROBENZO[1, 4]DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORP (FI) | 2014-09-03 | — | — | EP | disclosed |
| US-8809536-B2 | 2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases | ORION CORPORATION (FI) | 2014-08-19 | — | — | US | disclosed |
| US-20140179926-A1 | 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | ORION CORPORATION (FI) | 2014-06-26 | — | — | US | disclosed |
| US-8697723-B2 | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases | ORION CORPORATION (FI) | 2014-04-15 | — | — | US | disclosed |
| CN-101842369-B | 2, 3-dihydrobenzo [1,4] dioxin-2-ylmethyl derivatives as alpha 2C antagonists for the treatment of peripheral and central nervous system disorders | ORION CORP | 2014-01-22 | — | — | CN | disclosed |
| WO-1994007863-A9 | OCTAHYDRONAPHTHOQUINOLIZINES, AND METHODS OF MAKING AND USING THEREOF | — | 1994-06-09 | — | — | WO | disclosed |
| WO-1994007863-A1 | OCTAHYDRONAPHTHOQUINOLIZINES, AND METHODS OF MAKING AND USING THEREOF | NEW YORK UNIVERSITY (US) | 1994-04-14 | — | — | WO | disclosed |
| US-4937346-A | Phenyl-azacykloalkanes | Carlsson, Per Arvid Emil (SE) | 1990-06-26 | — | — | US | disclosed |
| EP-0084920-B1 | NEW COMPOUNDS USEFUL AS INTERMEDIATES OR STARTING MATERIALS FOR PREPARATION OF THERAPEUTICALLY USEFUL PHENYL-AZACYCLOALKANES | Carlsson, Per Arvid Emil (SE) | 1989-04-19 | — | — | EP | disclosed |
| US-4719219-A | Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders | Carlsson, Per A. E. (SE) | 1988-01-12 | — | — | US | disclosed |
| EP-0114603-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1984-08-01 | — | — | EP | disclosed |
| US-4426386-A | CNS DISORDERS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1984-01-17 | — | — | US | disclosed |
| EP-0084920-A2 | New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes | Carlsson, Per Arvid Emil (SE) | 1983-08-03 | — | — | EP | disclosed |
| EP-0030526-A1 | New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds | Astra Läkemedel Aktiebolag (SE) | 1981-06-17 | — | — | EP | disclosed |
| WO-1981001552-A1 | NEW PHENYL-AZACYCLOALKANES | ASTRA LAEKEMEDEL AB (SE) | 1981-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | DRD2 4505/4885DRD3 4541/4885CYP2D6 4324/4885 |
| US-20140179926-A1 | 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES | PMP22, NPY2R, ADRA2C | DRD2 204/4885DRD3 290/4885CYP2D6 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.